Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CML/021 "A Phase II Exploratory Study of IMATINIB High Dose (800mg/gg) in the Treatment of Newly Diagnosed Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase"

NCT00510926 is registered in ClinicalTrials.gov with University of Bologna as lead sponsor.

NCT NCT00510926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CML/021 "A Phase II Exploratory Study of IMATINIB High Dose (800mg/gg) in the Treatment of Newly Diagnosed Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase"
Lead sponsor
University of Bologna
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
November 30, 2006
Enrollment
80
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia, chronic, chronic-phase